Skip to main content

Hodgkin Lymphoma — Deal Benchmarks & Valuation

Median Upfront
$332M
Range: $185M - $469M
Total Deal Value
$2.1B
Range: $1.4B - $2.8B
Royalty Rate
12.7% - 20.8%
Tiered up to 24.8%
Dev Milestones
$443M
Range: $296M - $593M
Model Your Deal

Market Analysis

Hodgkin Lymphoma is one of the most actively transacted indications in oncology licensing. Phase 2 deals for hodgkin lymphoma carry a median total deal value of $2.1B, with upfront payments ranging from $185M to $469M. The recommended deal structure allocates approximately 16% to upfront payments and 84% to milestones.

Milestone structures for hodgkin lymphoma deals allocate $443M to development milestones, $709M to regulatory milestones, and $621M to commercial milestones. Royalty rates range from 12.7% to 20.8% at the base tier, with tiered escalation reaching 16.7%-24.8% on peak sales.

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What are typical deal terms for hodgkin lymphoma licensing?
Phase 2 hodgkin lymphoma licensing deals average $332M in upfront payments with $2.1B total deal value. The 16/84 upfront/milestone split reflects the risk profile at this clinical stage.
What royalty rates are standard for hodgkin lymphoma deals?
Base royalty rates for hodgkin lymphoma transactions range from 12.7% to 20.8%, with tiered escalations reaching 16.7%-24.8% on peak sales. Rates are influenced by mechanism differentiation, competitive positioning, and territorial scope.
How are hodgkin lymphoma deal milestones structured?
Hodgkin Lymphoma deals allocate approximately 84% of total deal value to milestones. Development milestones ($443M) make up the largest share, followed by commercial milestones ($621M) and regulatory milestones ($709M).
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Lung Cancer (NSCLC) Deals

View

Lung Cancer (SCLC) Deals

View

Breast Cancer (HER2+) Deals

View

Oncology Deal Overview

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating
For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included